港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

恒瑞医药

70.800

-0.300-0.42%

成交量：286.76万

成交额：2.05亿

市值：4,699.00亿

市盈率：64.73

高：72.600

开：70.900

低：70.700

收：71.100

52周最高：95.200

52周最低：52.500

股本：66.37亿

香港流通股本：2.58亿

量比：0.77

换手率：1.11%

股息：- -

股息率：- -

每股收益(LYR):1.094

净资产收益率：14.34%

总资产收益率：8.37%

市净率：7.22

市盈率(LYR):64.73

市销率: 13.87

数据加载中...

总览公司新闻资讯公告

医药健康行业研究：中药国采预计整体影响有限，拐点将至关注左侧优质资产

前三季度财报，净利润前10药企出炉

医药医疗专家热议国际化新策略：创新生态至关重要

恒瑞医药：HRS-2430注射液获得药物临床试验批准通知书

默沙东中国总裁唐凯宇：未来5年预计有40多项新产品和新适应证引入中国

国际金融报

从展品变商品越来越快，以上海为“舞台”，全球药企集体加码中国｜进博会

天风证券：连续三年跑输的行业哪些明年反转概率较大？

智通财经网

外资药企联手本土药企，中国正成为全球创新药策源地｜共享大市场

回顾10月，云顶新耀、恒瑞医药、华润医药等一批药企发生高管变动

中国创新药，10亿赌注的“药神”游戏

第一三共：终止3个研发项目

A+H板块添丁添财 AH股溢价结构分化

恒瑞医药(01276)将已回购的1351.11万股A股股份转移至员工持股计划

智通港股空仓持单统计|11月7日

恒瑞医药(600276.SH)：SHR-4610注射液获得药物临床试验批准通知书

2025年前三季度，跨国药企中的黑马是谁？

花旗集团在恒瑞医药的H股多头头寸于11月3日降至4.67%，较5.30%有所减少

跨国药企中国两条腿走路：加速全球引进，与本土创新药一起出海

恒瑞医药11月07日主力净流出495.6万元散户资金买入

智通AH统计|11月7日

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/01276/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":70.8,"timestamp":1763453299003,"preClose":71.1,"halted":0,"volume":2867625,"delay":0,"floatShares":258000000,"shares":6637000000,"eps":1.0937645923481618,"marketStatus":"收市竞价","change":-0.3,"latestTime":"11-18 16:09:01","open":70.9,"high":72.6,"low":70.7,"amount":205288749,"amplitude":0.026723,"askPrice":70.85,"askSize":4600,"bidPrice":70.8,"bidSize":12600,"shortable":3,"etf":0,"ttmEps":1.268994430159076,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1763453400000},"marketStatusCode":4,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":71.1,"openAndCloseTimeList":[[1763429400000,1763438400000],[1763442000000,1763452800000]],"volumeRatio":0.76824,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":61.78,"timestamp":1763449200000,"preClose":61.8,"halted":0,"volume":21910000,"delay":0,"premium":"+4.78"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.37%","roe":"14.34%","lyrEps":1.093765,"volumeRatio":0.76824,"shares":6637000000,"dividePrice":0,"high":72.6,"amplitude":0.026723,"preClose":71.1,"low":70.7,"week52Low":52.5,"pbRate":"7.22","psRate":"13.87","week52High":95.2,"institutionHeld":0,"latestPrice":70.8,"committee":0.465116,"eps":1.0937645923481618,"divideRate":0,"volume":2867625,"delay":0,"ttmEps":1.268994430159076,"open":70.9,"prevYearClose":44.05,"prevWeekClose":71.6,"prevMonthClose":75.2,"prevQuarterClose":88.8,"fiveDayClose":70.85,"twentyDayClose":79.25,"sixtyDayClose":77.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.5714,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1760716800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2025-11-17","current":55.792207,"percent":0.292683,"low":50.027905,"twenty":52.873142,"median":57.752122,"eighty":62.273725,"high":65.582363,"avg":57.75041,"sd":4.614457,"marketCap":448676436005.11},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-17","current":54.931735,"twenty":52.873142,"median":57.752122,"eighty":62.273725,"marketCap":448676436005.11}],"updateTime":1763453341580},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582891515","title":"医药健康行业研究：中药国采预计整体影响有限，拐点将至关注左侧优质资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2582891515","media":"国金证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582891515?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 18:06","pubTimestamp":1762682818,"startTime":"0","endTime":"0","summary":"投资逻辑上周创新药板块有所回调，主要是短期无重大催化剂，同时市场等待12月初即将披露的医保谈判结果落地。全国中成药联盟第四批集采目录公布，我们预计对中药上市公司整体影响有限，此前市场的担忧有望得以缓解。经历前期回调后，建议关注处于估值低位的优质资产，如华润三九、益丰药房等。派威妥为国内首个且目前唯一获批的靶向PSMA的放射配体疗法药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109180701975df686&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109180701975df686&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348735423.USD","01302","LU0348783233.USD","LU0561508036.HKD","LU2778985437.USD","BK1161","LU0348825331.USD","LU1794554557.SGD","LU0348767384.USD","LU1961090484.USD","LU1720050803.USD","LU0540923850.HKD","LU2488822045.USD","LU0348827113.USD","LU0417516571.SGD","IE00BPRC5H50.USD","01801","IE00B5MMRT66.SGD","LU0634319403.HKD","LU0417516738.SGD","LU0348784397.USD","LU2399975544.HKD","01276","LU2476274720.SGD","BK1574","09926","LU0417516902.SGD","IE00B543WZ88.USD","LU2476274308.USD","LU0348766576.USD"],"gpt_icon":0},{"id":"2582823663","title":"前三季度财报，净利润前10药企出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2582823663","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582823663?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 17:31","pubTimestamp":1762680660,"startTime":"0","endTime":"0","summary":"2025年前三季度，A股497家药企中净利润排名前十的企业依次为药明康德、迈瑞医疗、恒瑞医药、新和成、上海医药等。药明康德以120.76亿元的归母净利润位居榜首，同比增长84.84%，主要得益于CRDMO业务模式的持续聚焦及优化，以及出售联营企业部分股票的收益。迈瑞医疗归母净利润达75.70亿元，三大核心业务稳健发展，尤其体外诊断业务表现突出。恒瑞医药归母净利润为57.51亿元，通过创新药研发和全球化布局实现高质量发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110010516975e7987&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110010516975e7987&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","BK1191","LU0359202008.SGD","LU0359201612.USD","01276","LU0359201885.HKD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2582654823","title":"医药医疗专家热议国际化新策略：创新生态至关重要","url":"https://stock-news.laohu8.com/highlight/detail?id=2582654823","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582654823?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 17:09","pubTimestamp":1762679382,"startTime":"0","endTime":"0","summary":"在9日举办的第八届中国国际进口博览会上海会议活动“2025生命健康大会”上，来自医药研发、医疗服务、药械投资等领域的多位业界人士针对上述问题提出了新观点。其中，出口额487.5亿美元，同比增长了7.3%。谈及药企出海新策略，张连山表示，恒瑞实际上与GSK、Merck（默克）均有2～3次的深度合作。王海蛟称，除了AI技术外，为医疗、医药提供创新生态也至关重要。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109171051a6ecab55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109171051a6ecab55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU1023057109.AUD","BK1574","BK1191","LU2543165471.USD","BK1515","09939","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","01276"],"gpt_icon":0},{"id":"2582898275","title":"恒瑞医药：HRS-2430注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582898275","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582898275?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 11:31","pubTimestamp":1762659060,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　恒瑞医药（01276）发布公告，近日，公司收到国家药品监督管理局核准签发关于HRS-2430注射液的《药物临床试验批准通知书》，将于近期开展临床试验。\n　　HRS-2430注射液为静脉全身麻醉药，已上市的同类产品有依托咪酯、咪达唑仑、瑞马唑仑等。经查询，2024年依托咪酯、咪达唑仑、瑞马唑仑全球销售额合计约为7.73亿美元。截至目前，HRS-2430注射液相关项目累计研发投入约2460万元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-11-09/doc-infwunpw8903293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064131003.USD","LU2097828714.EUR","LU1580142542.USD","600276","LU2289578879.USD","LU2097828805.USD","LU1064130708.USD","LU1146622755.USD","LU1655091616.SGD","LU1820825898.SGD","LU2097828557.USD","BK0012","LU1997244956.HKD","01276","BK0188","LU1255011170.USD","LU1969619763.USD","LU2097828631.EUR","LU2543165471.USD","LU1781817850.SGD","LU0359201885.HKD","LU2488822045.USD","BK0028","BK0239","LU0359201612.USD","LU0405327148.USD","LU2580892789.USD","LU1328615791.USD","LU1997245177.USD","LU2495084118.USD","BK1191","LU0405327494.USD","LU2580892862.HKD","LU2328871848.SGD","LU0359202008.SGD","BK0060","LU1023057109.AUD","LU1997245094.SGD","BK0183","LU2148510915.USD","BK0196","LU2097828474.EUR"],"gpt_icon":0},{"id":"2582174866","title":"默沙东中国总裁唐凯宇：未来5年预计有40多项新产品和新适应证引入中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2582174866","media":"国际金融报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582174866?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 20:14","pubTimestamp":1762604040,"startTime":"0","endTime":"0","summary":"唐凯宇透露，“未来五年，默沙东预计将有40多项新产品和新适应证引入中国，这将极大地丰富我们的产品管线，满足更多患者的需求。”肿瘤防治方面，默沙东HPV疫苗于今年获批适用于男性预防HPV相关癌症和疾病；肿瘤治疗药物截至今年8月累计获批32个适应证，涵盖中国多种发病率高、生存率低、治疗难度大的癌种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108202622a6eafea1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108202622a6eafea1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","01276","LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2581857293","title":"从展品变商品越来越快，以上海为“舞台”，全球药企集体加码中国｜进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2581857293","media":"上海科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581857293?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 18:29","pubTimestamp":1762597799,"startTime":"0","endTime":"0","summary":"去年9月，已在中国提交上市申请。第六届进博会上，诺和诺德展出了全球首个用于长期体重管理的GLP-1RA周制剂的临床研究文献，7个月后，该产品在中国获批上市。第八届进博会前宣布加码中国市场的还有赛诺菲。这被业内视为今年中国国产创新药加速融入全球医药产业体系的标杆。截至目前，超过80%的GSK中国研发项目已并入其全球同步开发进程，超过20项临床研究项目正在开展。未来3年，GSK约有18项新产品及新适应证将在中国获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108183728a6ead625&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108183728a6ead625&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","KWEB","FXI","CWEB","BK4007","BK4614","ASHR","NVO","MCHI","BK4532","LU1093756325.SGD","BK4588","BK4599","01276","BK4585","LU0154236417.USD","DRAG","YINN","ASHS","CQQQ","CHAU"],"gpt_icon":1},{"id":"2582786453","title":"天风证券：连续三年跑输的行业 哪些明年反转概率较大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2582786453","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582786453?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 17:31","pubTimestamp":1762594294,"startTime":"0","endTime":"0","summary":"现在连续三年跑输但第四年跑赢概率较大的行业有食品饮料、农林牧渔、社会服务、医药生物。综合条件概率与各行业连续趋势性跑输的最大周期，我们发现环保、公用事业、交通运输这些“防御性行业”，更容易长期跑输。当前已经连续三年跑输，且接近其历史跑输最长周期的行业有美容护理、基础化工、社会服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108174507a6eac18d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108174507a6eac18d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","01276","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2582866170","title":"外资药企联手本土药企，中国正成为全球创新药策源地｜共享大市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2582866170","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582866170?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 16:05","pubTimestamp":1762589120,"startTime":"0","endTime":"0","summary":"实际上，最近几年，中国创新药在全球医药市场中已变得不可忽视。安斯泰来中国区总裁赵萍表示，中国已经成为全球药物创新的策源地，也是安斯泰来集团最重要的全球市场之一。该全球首例患者入组即由中国研发中心完成。跨国药企积极牵手本土创新药企国内临床研究机构与研究者实力增强，行业政策不断向好，令中国区对跨国药企愈发重要的同时，也成为本土创新药公司发展的肥沃土壤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108160608a4923a29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108160608a4923a29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01276","BK1191","03692","LU0359201885.HKD","LU0359201612.USD","LU0359202008.SGD","LU2543165471.USD","06978","BK1574","02142","LU1023057109.AUD"],"gpt_icon":0},{"id":"2582286617","title":"回顾10月，云顶新耀、恒瑞医药、华润医药等一批药企发生高管变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2582286617","media":"制药网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582286617?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 10:13","pubTimestamp":1762568022,"startTime":"0","endTime":"0","summary":"从管理层到核心技术人员，今年10月份，医药行业人事变动浪潮席卷。如云顶新耀宣布委任吴以芳为公司董事会主席，其同时获委任提名委员会主席及薪酬委员会成员。吴以芳加入云顶新耀，有望为云顶新耀带来多方面积极影响。恒瑞医药宣布任命尹航为恒瑞医药肿瘤事业部总经理，尹航将直接向恒瑞医药总裁冯佶汇报工作。赛隆药业发布董事长及两位副总裁人事变动公告。沈旗原定任期至 2027 年 8 月 15 日，离任不影响公司正常运作及经营管理 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108101528a6ea1037&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108101528a6ea1037&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU0359201612.USD","01276","BK1570","LU1023057109.AUD","LU0359201885.HKD","LU2543165471.USD","BK1574","01952","LU0359202008.SGD","BK1191","BK1161","03320"],"gpt_icon":1},{"id":"2581853688","title":"中国创新药，10亿赌注的“药神”游戏","url":"https://stock-news.laohu8.com/highlight/detail?id=2581853688","media":"36氪","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581853688?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 09:15","pubTimestamp":1762564545,"startTime":"0","endTime":"0","summary":"而中国创新药，恰好成了这个货架上，最亮眼的商品。这是全球首个，且唯一在3期临床中击败K药的药。因为创新药从诞生那一刻起，就是一个全球化的行业。中国的创新药企属于是边和世界交手，边刻苦研发，结结实实吃过不少亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108092200a6e9f7fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108092200a6e9f7fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516738.SGD","LU2476274308.USD","LU0348784397.USD","LU0634319403.HKD","LU2488822045.USD","LU0348825331.USD","09926","LU0348735423.USD","02359","IE00B5MMRT66.SGD","LU0348783233.USD","LU1720050803.USD","BK1574","01276","LU2778985437.USD","LU1794554557.SGD","LU0417516571.SGD","LU2476274720.SGD","LU0417516902.SGD","LU0348767384.USD","LU0561508036.HKD","BK1161","LU0348766576.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU2399975544.HKD","IE00BPRC5H50.USD","LU1961090484.USD","06978","LU0348827113.USD"],"gpt_icon":0},{"id":"2582866177","title":"第一三共：终止3个研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2582866177","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582866177?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 08:02","pubTimestamp":1762560124,"startTime":"0","endTime":"0","summary":"近日，日本制药巨头第一三共在其2025年中决算说明会上，不仅公布了亮眼的半年度业绩，更向外界清晰地展示了其未来研发的战略布局。在重点介绍其核心ADC管线进展的同时，公司也明确宣布：终止3条处于临床阶段的研发管线。强劲的现金流入为第一三共的持续研发和创新提供了坚实保障。在巩固现有布局的同时，第一三共近期启动了多项新的临床研究，为其管线注入新的动力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108081053a4917109&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108081053a4917109&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","BK1191","LU1023057109.AUD","LU0359201885.HKD","09995","LU0359202008.SGD","LU0359201612.USD","01276"],"gpt_icon":0},{"id":"2581833617","title":"A+H板块添丁添财 AH股溢价结构分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2581833617","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581833617?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 02:13","pubTimestamp":1762539206,"startTime":"0","endTime":"0","summary":"新上市H股表现分化近期，多家知名A股企业成功登陆港股市场，为A+H板块注入了新的活力，也成为影响AH股溢价指数走势的重要因素。AH股溢价结构分化加剧尽管多数A+H股仍维持A股溢价格局，但截至11月7日收盘，有5只A+H股出现“价格倒挂”。事实上，今年以来AH股溢价结构分化加剧，以往A股相对H股超过300%溢价的现象已经消失。Wind统计显示，目前166只A+H股中，溢价率超过100%的仅有30家，其中6家溢价率在200%以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108021558975b2151&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108021558975b2151&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09927","02833","BK1610","MHImain","MCHmain","01033","LU1993786604.SGD","03968","HHImain","HSI","00638","03678","02359","01276","LU1960683339.HKD","LU1807302812.USD","06031","00699","03606","00300","513600","BK1116","02899","03750"],"gpt_icon":1},{"id":"2581098710","title":"恒瑞医药(01276)将已回购的1351.11万股A股股份转移至员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2581098710","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581098710?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 18:50","pubTimestamp":1762512637,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2025年11月7日，将已回购的1351.11万股A股股份转移至员工持股计划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1255011170.USD","LU2289578879.USD","LU1023057109.AUD","LU0359201612.USD","LU2543165471.USD","LU0359202008.SGD","BK0239","159982","LU1580142542.USD","LU2148510915.USD","LU2097828714.EUR","LU1781817850.SGD","LU2097828805.USD","LU1655091616.SGD","LU1146622755.USD","LU1064131003.USD","LU1820825898.SGD","BK0012","BK0028","LU2495084118.USD","LU1969619763.USD","BK0183","LU1997245094.SGD","LU2488822045.USD","LU1997245177.USD","LU2097828474.EUR","LU0405327494.USD","399300","LU2580892789.USD","BK0060","LU2580892862.HKD","LU1997244956.HKD","600276","LU2097828557.USD","BK0196","LU2097828631.EUR","BK0188","LU1064130708.USD","LU2328871848.SGD","LU0405327148.USD","LU1328615791.USD","01276","BK1191","LU0359201885.HKD"],"gpt_icon":0},{"id":"2581006680","title":"智通港股空仓持单统计|11月7日","url":"https://stock-news.laohu8.com/highlight/detail?id=2581006680","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581006680?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 18:30","pubTimestamp":1762511405,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止10月31日，未平仓空单比位列前三位为中兴通讯、万科企业、中远海控，空仓比分别为17.15%、16.07%、15.03%。智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；以上涉及的空仓比增加值或减少值为绝对值数。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1880383366.USD","HPAD.SI","BK1513","BK1619","LU0196878994.USD","BK1149","82318","06865","03145","BK1190","03750","00853","01919","LU0588545904.SGD","01171","00358","601318","BK1103","02318","LU0588545730.USD","06682","PNGAY","02208","00772","09688","01816","BK1610","BK1147","03347","02202","000002","LU0106252389.USD","06060","PAImain","01428","03800","06821","02331","LU0348827113.USD","01880","02696","LU0359202008.SGD","00763","01276","LNNGY","82331","BK1512","01772","02899"],"gpt_icon":1},{"id":"2581100345","title":"恒瑞医药(600276.SH)：SHR-4610注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2581100345","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581100345?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 17:48","pubTimestamp":1762508909,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司上海盛迪医药有限公司收到国家药品监督管理局(简称“国家药监局”)核准签发关于SHR-4610注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-4610注射液是公司自主研发的创新型抗肿瘤药物，在临床前动物模型中展现出良好的抗肿瘤活性，拟用于治疗晚期实体瘤。截至目前，SHR-4610注射液相关项目累计研发投入约736万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","BK0196","LU1820825898.SGD","BK0188","01276","BK0060","LU1969619763.USD","LU2543165471.USD","LU1064131003.USD","LU1255011170.USD","LU0405327494.USD","LU2328871848.SGD","BK0239","LU1023057109.AUD","LU1997244956.HKD","LU1781817850.SGD","LU2097828474.EUR","LU1997245094.SGD","BK1191","LU0359202008.SGD","LU2097828714.EUR","LU2289578879.USD","BK0012","LU2097828805.USD","LU0359201612.USD","BK0183","BK0028","LU0359201885.HKD","LU1064130708.USD","LU1655091616.SGD","LU2495084118.USD","600276","LU0405327148.USD","LU2488822045.USD","LU1580142542.USD","LU1328615791.USD","LU1146622755.USD","LU2097828631.EUR","LU2580892862.HKD","LU1997245177.USD","LU2580892789.USD","LU2097828557.USD"],"gpt_icon":0},{"id":"2581003317","title":"2025年前三季度，跨国药企中的黑马是谁？","url":"https://stock-news.laohu8.com/highlight/detail?id=2581003317","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581003317?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 17:31","pubTimestamp":1762507919,"startTime":"0","endTime":"0","summary":"截至 11 月 6 日，2025 年第三季度全球1-10 跨国药企财报悉数披露，强生、罗氏、默沙东凭借多元化业务布局继续稳坐前三宝座，但榜单背后的增长动力已悄然生变 —— 礼来以 54% 的同比增速靠前，成为本季度最大黑马，其强劲表现不仅印证了 GLP-1 类药物的统治力，更揭示了全球制药行业 “代谢领域为王” 的新竞争法则。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107173430a6e85233&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107173430a6e85233&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","LU0154236417.USD","LU1093756325.SGD","BK4588","BK4007","IE00BZ1G4Q59.USD","BK4585","01276","LU1093756168.USD","NVO","BK4532","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"1197054802","title":"花旗集团在恒瑞医药的H股多头头寸于11月3日降至4.67%，较5.30%有所减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1197054802","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197054802?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 17:18","pubTimestamp":1762507100,"startTime":"0","endTime":"0","summary":"花旗集团在恒瑞医药的H股多头头寸于11月3日降至4.67%，较之前的5.30%有所减少。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","LU1255011170.USD","BK0028","LU2328871848.SGD","BK0188","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","LU1146622755.USD","LU2148510915.USD","LU2097828805.USD","LU0405327148.USD","LU1969619763.USD","LU2495084118.USD","LU1580142542.USD","LU2488822045.USD","LU2289578879.USD","LU1997245094.SGD","LU2580892862.HKD","BK0183","LU1655091616.SGD","LU2580892789.USD","BK0196","LU0359201612.USD","600276","LU2097828474.EUR","LU1997244956.HKD","LU1064131003.USD","LU1997245177.USD","LU2097828631.EUR","BK0060","BK1191","LU0405327494.USD","LU2097828714.EUR","BK0012","LU1820825898.SGD","LU1328615791.USD","LU2097828557.USD","LU1781817850.SGD","BK0239","LU2543165471.USD","01276"],"gpt_icon":0},{"id":"2581880053","title":"跨国药企中国两条腿走路：加速全球引进，与本土创新药一起出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2581880053","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581880053?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 17:03","pubTimestamp":1762506236,"startTime":"0","endTime":"0","summary":"随着中国在生物制药领域的快速发展，多家跨国药企负责人表示，他们的中国策略进行了相应调整：既要加强中国市场投入，加速把全球创新产品引入中国市场，也要通过BD交易等方式，与中国创新共同拓展全球市场。GSK中国也希望成为GSK全球的创新中心。“我们会把中国纳入第一阵营，让中国参与全球临床试验的早期阶段，这样能够加速创新药物的上市，尽快惠及中国患者。”目前，中国是凯西在全球最有爆发力的市场之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107170601a6e83e05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107170601a6e83e05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","01276","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","06978","LU1023057109.AUD","BK1161","BK1574"],"gpt_icon":0},{"id":"2581005089","title":"恒瑞医药11月07日主力净流出495.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2581005089","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581005089?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 16:15","pubTimestamp":1762503319,"startTime":"0","endTime":"0","summary":"11月07日, 恒瑞医药股价跌3.45%，报收69.95元，成交金额2.2亿元，换手率1.21%，振幅4.07%，量比0.73。恒瑞医药今日主力资金净流出495.6万元，上一交易日主力净流入2820.1万元。该股近5个交易日下跌6.45%，主力资金累计净流入7666.5万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入8452.3万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107161612975a15f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107161612975a15f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","BK1191","LU0359201612.USD","LU1023057109.AUD","01276","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":1},{"id":"2581065074","title":"智通AH统计|11月7日","url":"https://stock-news.laohu8.com/highlight/detail?id=2581065074","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581065074?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 16:15","pubTimestamp":1762503306,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止11月7日收盘，东北电气、弘业期货、中石化油服分列AH溢价率前三位，溢价率分别为881.82%、264.44%、259.74%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-15.21%、-0.64%、5.72%。其中东北电气、弘业期货、长飞光纤光缆的偏离值位居前三，分别为47.50%、26.95%、26.59%；另外，中远海能、中国东方航空股份、中国人寿的偏离值位居后三，分别为-13.87%、-11.53%、-11.12%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03968","LU0880133367.SGD","00753","LU1366334578.USD","BK1554","03678","00042","00670","02359","03750","BK1551","LU0072913022.USD","01033","01057","LU0648948544.HKD","LU0348805143.USD","01919","BK1133","00895","01812","06178","159982","06031","IE00BVYPNQ40.USD","00728","399300","02899","01349","LU0051755006.USD","02600","02465","02218","03143","01108","06869","06826","SG9999002828.SGD","00187","01276","02883","00300","02628","03606","01138","01988","BK1544","01375"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}